338 related articles for article (PubMed ID: 24275248)
21. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
Wu B; Yang Y; Qin X; Zhang S; Jing C; Zhu C; Ma B
ChemMedChem; 2013 Dec; 8(12):1913-7. PubMed ID: 24115741
[TBL] [Abstract][Full Text] [Related]
23. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Banala VT; Urandur S; Sharma S; Sharma M; Shukla RP; Marwaha D; Gautam S; Dwivedi M; Mishra PR
Biomater Sci; 2019 Jun; 7(7):2889-2906. PubMed ID: 31086900
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules.
Okayama N; Omi H; Okouchi M; Imaeda K; Kato T; Akao M; Imai S; Shimizu M; Fukutomi T; Itoh M
J Diabetes Complications; 2002; 16(5):321-6. PubMed ID: 12200074
[TBL] [Abstract][Full Text] [Related]
25. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via Kvβ1.1 (AKR6A8) subunit of voltage-gated potassium channel.
Tur J; Badole SL; Cheng F; Das A; Kukreja RC; Tipparaju SM
Mol Cell Biochem; 2017 Dec; 436(1-2):71-78. PubMed ID: 28585087
[TBL] [Abstract][Full Text] [Related]
27. LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Nirogi R; Kandikere V; Ajjala DR; Bhyrapuneni G; Muddana NR
J Pharm Biomed Anal; 2013 Feb; 74():227-34. PubMed ID: 23245255
[TBL] [Abstract][Full Text] [Related]
28. [Improved method of epalrestat synthesis].
Sheng R; Liu T; Hu YZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Aug; 32(4):356-8. PubMed ID: 12970944
[TBL] [Abstract][Full Text] [Related]
29. Ischemic postconditioning during reperfusion attenuates oxidative stress and intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion via aldose reductase.
Wen SH; Ling YH; Li Y; Li C; Liu JX; Li YS; Yao X; Xia ZQ; Liu KX
Surgery; 2013 Apr; 153(4):555-64. PubMed ID: 23218881
[TBL] [Abstract][Full Text] [Related]
30. QM/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy.
Choudhary S; Kumar M; Silakari O
Bioorg Chem; 2021 Mar; 108():104556. PubMed ID: 33376013
[TBL] [Abstract][Full Text] [Related]
31. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
32. Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis.
Kadam A; Dawane B; Pawar M; Shegokar H; Patil K; Meshram R; Gacche R
Bioorg Chem; 2014 Apr; 53():67-74. PubMed ID: 24607578
[TBL] [Abstract][Full Text] [Related]
33. Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro.
Sturm K; Levstik L; Demopoulos VJ; Kristl A
Eur J Pharm Sci; 2006 May; 28(1-2):128-33. PubMed ID: 16497491
[TBL] [Abstract][Full Text] [Related]
34. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
35. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
36. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
37. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
38. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
39. Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach.
Choudhary S; Silakari O
J Biomol Struct Dyn; 2022 Aug; 40(13):6052-6070. PubMed ID: 33480327
[TBL] [Abstract][Full Text] [Related]
40. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
